WASHINGTON/JERUSALEM (REUTERS) - Pfizer said on Monday (June 6) it would spend US$120 million (S$165 million) to expand manufacturing of its Covid-19 antiviral treatment at its Michigan plant, as demand ramps up.
Use of the pill, Paxlovid, authorised to treat newly infected, at-risk people to prevent severe illness, has soared recently as infections rise.
Biden administration officials have pushed for the wider use of Paxlovid, which the government distributes for free.
Meanwhile, Paxlovid has been found to reduce Covid-19 hospitalisation and death rates in vaccinated and unvaccinated patients 65 years and older, according to a new study in Israel conducted during the rise of the Omicron variant of the coronavirus.
The treatment, however, was not found to prevent severe illness among younger adults, according to research from Clalit Health Services, Israel’s largest healthcare provider.
Pfizer’s clinical trial tested Paxlovid in unvaccinated people who had risk factors for serious disease and found that the two-drug treatment cut the risk of hospitalisation and death by 90%. That was during the Delta wave of the virus.
There has been some concern, amid anecdotal reports of bounce-back Covid symptoms after patients get relief from taking Paxlovid, that the treatment might not be as effective in vaccinated patients.
The Israeli study, which was published without peer review as a preprint by online platform Research Square, included data from nearly 110,000 participants between Jan 9 to March 10, when Omicron was the country’s dominant coronavirus variant.
Senior citizens who had no prior immunity – meaning they were neither vaccinated nor recovered from a previous Covid case - saw an 86% drop in hospitalisations with Paxlovid. Those who had prior immunity also benefited, but at a lower rate of 60%.
In total, 0.6% of those 65 and older treated with Paxlovid - or 14 of 2,504 – had to be hospitalised. Those who did not receive Paxlovid were hospitalised about three times more often, or 762 out of 40,315.
In patients ages 40-64, however, regardless of their prior immunity, the data showed no significant benefit in reducing hospitalisation, said Clalit researcher Ronen Arbel.
In reducing mortality, Arbel said the treatment showed a very high benefit in patients 65 and older – an 81% risk reduction. There were no observed benefits in younger adults, who are at less risk of dying from Covid.
The researchers noted limitations that may have biased their findings, such as lack of data on the symptoms patients presented, which may have impacted their course of treatment, or patients’ degrees of prior immunity.
